Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001 in relapsed/refractory Multiple Myeloma (r/rMM) at ASH Annual Meeting

Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution)

Glenmark Pharma reports consolidated revenue growth of 7.1% and EBITDA growth of 30.2% YoY for Q2 FY 2024-25

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)

Glenmark Pharma reports consolidated revenue growth of 6.9%, EBITDA margin of 18.1%, and PAT margin of 10.5% YoY for Q1 FY 2024-25

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg

Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)

Glenmark Pharma Reports Q4 FY2023-24 Financial results

Glenmark and BeiGene Enter into an Agreement for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

Glenmark Pharmaceuticals receives ANDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals receives ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24

Glenmark partners with Pfizer to launch Abrocitinib in India

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance ‐ ‘Ichnos Glenmark Innovation’

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Glenmark is the first to launch Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India